Hemab Therapeutics (COAG) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on therapies for blood coagulation disorders, aiming to build a leading franchise in this area.

• Lead asset, sutacimig, is a bispecific antibody in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency; HMB-002 is a monovalent antibody in Phase 1/2 for Von Willebrand Disease.

• Strategic roadmap targets 2 commercial medicines, 2 late-stage, and 2 early-stage clinical programs by 2030.

• All global economic development and commercialization rights to assets are retained.

Financial performance and metrics

• Net losses were $48.7 million in 2024 and $63.9 million in 2025; accumulated deficit of $181.9 million as of December 31, 2025.

• Cash, cash equivalents, and marketable securities totaled $185.5 million at year-end 2025.

• Research and development expenses increased from $41.4 million in 2024 to $59.6 million in 2025.

• General and administrative expenses rose from $9.0 million in 2024 to $10.5 million in 2025.

• No revenue from product sales to date; operations funded primarily through private placements and convertible debt.

Use of proceeds and capital allocation

• Net proceeds, together with existing cash, will fund clinical development of sutacimig and HMB-002, additional discovery, preclinical, and clinical activities, and general corporate purposes.

• Proceeds are not expected to fund any product candidate through regulatory approval; additional capital will be needed.